Bayer today announced the appointment of Brenda L. Raphael as Senior Vice President and General Manager of the Therapeutics Business Unit of Consumer Health Commercial Operations North America, effective October 30, 2017.

"Brenda has more than 20 years of experience in leading successful billion-dollar, consumer-focused brands," said Natalie Bartner, President of North America Consumer Health, Consumer Health Division, Bayer. "Her strengths in understanding customers, marketing and innovation will lead the Therapeutics Business Unit to continue developing self-care solutions that help people live healthier lives."

Ms. Raphael joins Bayer from Pfizer, Inc., where she most recently held the position of General Manager for U.S. Brands in Pharma at the company's New York City offices. She also previously held various senior positions at the Coca-Cola Company and Procter & Gamble.

With experience that spans pharmaceuticals and consumer products, Ms. Raphael delivered significant financial gains to the businesses, and insight-driven multi-channel marketing to consumers.

Ms. Raphael holds a Masters of Business Administration degree from the Darden Graduate School of Business at the University of Virginia, and a Bachelor of Science degree from Cornell University in New York.

Ms. Raphael will report to Natalie Bartner, and will be a member of the Consumer Health North America Leadership Team. She will be based in Whippany, New Jersey, U.S.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.